Apr 7, 2021 · Second, the authors used anakinra in combination with high-dose methylprednisolone and intravenous immunoglobulins. Especially the use of high dosages of …

Mar 12, 2024 · Background Endotype classification may guide immunomodulatory management of patients with bacterial and viral sepsis. We aimed to identify immune endotypes and …

Oct 6, 2020 · Anakinra (IL-1α and IL-1β blocker) has shown greatly reduced mortality, need for invasive mechanical ventilation, and bettering oxygenation status in severe COVID-19 patients …

Dec 10, 2020 · Background A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known …

May 28, 2024 · Despite significant progress in our understanding of the pathophysiology of sepsis and extensive clinical research, there are few proven therapies addressing the underlying …

Dec 6, 2023 · Anakinra treatment provided higher odds for clinical improvement and lowered the 28-day mortality from 6.9 to 3.2%. SuPAR and MAS features illustrate the biological and …

Jul 18, 2020 · Anakinra blocks the IL-1 receptor (IL-1R) and thus will prevent autoinflammation by blocking effects of IL-1α released from dead epithelial cells, as well as IL-1β produced by …

Sep 6, 2023 · Background One of five global deaths are attributable to sepsis. Hyperferritinemic sepsis (> 500 ng/mL) is associated with increased mortality in single-center studies. Our …

Jan 12, 2017 · Indeed, the interleukin (IL)-1 receptor blockade phase 3 trial published in 1997 showed no effect of immune suppression with anakinra on mortality in patients suffering from …

Feb 27, 2024 · Conclusion We identify an association between endotypes dened using blood transcriptome and anakinra therapy for COVID‑19 pneumonia, with anakinra‑treated patients …